CA2251169A1 - Quaternary cytofectins - Google Patents

Quaternary cytofectins

Info

Publication number
CA2251169A1
CA2251169A1 CA002251169A CA2251169A CA2251169A1 CA 2251169 A1 CA2251169 A1 CA 2251169A1 CA 002251169 A CA002251169 A CA 002251169A CA 2251169 A CA2251169 A CA 2251169A CA 2251169 A1 CA2251169 A1 CA 2251169A1
Authority
CA
Canada
Prior art keywords
quaternary
lipids
cytofectins
transfective
derivatized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002251169A
Other languages
French (fr)
Other versions
CA2251169C (en
Inventor
Carl J. Wheeler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fresh Tracks Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2251169A1 publication Critical patent/CA2251169A1/en
Application granted granted Critical
Publication of CA2251169C publication Critical patent/CA2251169C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Abstract

Cationic lipids, having a derivatized quaternary ammonium head group, that provide improved cell targeting ability and enhanced transfective efficacy for the delivery of molecules into cells. The lipids comprise a linker having funtional groups that provide sites for further attachment of drugs, cell receptor ligands or other bioactive agents.
CA002251169A 1996-04-09 1997-04-08 Quaternary cytofectins Expired - Fee Related CA2251169C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/629,965 US5994317A (en) 1996-04-09 1996-04-09 Quaternary cytofectins
US08/629,965 1996-04-09
PCT/US1997/005757 WO1997037966A1 (en) 1996-04-09 1997-04-08 Quaternary cytofectins

Publications (2)

Publication Number Publication Date
CA2251169A1 true CA2251169A1 (en) 1997-10-16
CA2251169C CA2251169C (en) 2006-12-19

Family

ID=24525211

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002251169A Expired - Fee Related CA2251169C (en) 1996-04-09 1997-04-08 Quaternary cytofectins

Country Status (9)

Country Link
US (1) US5994317A (en)
EP (1) EP0902780B1 (en)
JP (1) JP4031045B2 (en)
AT (1) ATE207874T1 (en)
CA (1) CA2251169C (en)
DE (1) DE69707870T2 (en)
DK (1) DK0902780T3 (en)
ES (1) ES2166540T3 (en)
WO (1) WO1997037966A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US6867195B1 (en) * 1989-03-21 2005-03-15 Vical Incorporated Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE162219T1 (en) 1989-11-16 1998-01-15 Univ Duke TRANSFORMATION OF ANIMAL SKIN CELLS USING PARTICLES
US6706694B1 (en) 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US7105574B1 (en) 1999-03-26 2006-09-12 Vical Incorporated Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
CA2309766C (en) 1997-11-20 2008-09-30 Vical Incorporated Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
US20040120891A1 (en) 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
ATE549032T1 (en) * 1999-03-26 2012-03-15 Vical Inc ADJUVANCE COMPOUNDS FOR IMPROVEMENT OF IMMUNE RESPONSES TO POLYNUCLEOTIDE-BASED VACCINES
WO2001017945A1 (en) * 1999-09-03 2001-03-15 The Procter & Gamble Company Cationic alkyl alkoxylate derivatives
EP1278551A2 (en) * 2000-04-21 2003-01-29 Vical Incorporated Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics
US20040204379A1 (en) * 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
KR100381512B1 (en) 2000-09-21 2003-04-26 굿젠 주식회사 Cationic lipids and use thereof
CA2436830A1 (en) * 2000-11-06 2002-06-20 Asilomar Pharmaceuticals, Inc. Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins
WO2002098465A2 (en) * 2001-06-07 2002-12-12 Celator Technologies, Inc. Cell penetrating therapeutic agents
US8496961B2 (en) 2002-05-15 2013-07-30 Sutter West Bay Hospital Delivery of nucleic acid-like compounds
AU2003278776A1 (en) * 2002-09-10 2004-04-30 Vical Incorporated Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection
JP4917263B2 (en) * 2002-12-23 2012-04-18 バイカル インコーポレイテッド Method for lyophilizing nucleic acid / block copolymer / cationic surfactant complex
JP5390059B2 (en) 2002-12-23 2014-01-15 バイカル インコーポレイテッド Method for producing sterile polynucleotide drug
US8080642B2 (en) * 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
ES2347340T3 (en) 2004-09-13 2010-10-28 Genzyme Corporation MULTIMERICAL CONSTRUCTIONS.
WO2006060723A2 (en) * 2004-12-03 2006-06-08 Vical Incorporated Methods for producing block copolymer/amphiphilic particles
US20080299182A1 (en) * 2007-03-01 2008-12-04 Shuyuan Zhang Methods and formulations for topical gene therapy
AU2011245987B2 (en) * 2010-04-28 2016-12-15 Kyowa Hakko Kirin Co., Ltd Cationic lipid
WO2011136369A1 (en) * 2010-04-28 2011-11-03 協和発酵キリン株式会社 Cationic lipid
JP2013095755A (en) * 2011-11-02 2013-05-20 Kyowa Hakko Kirin Co Ltd Cationic lipid
HRP20211424T2 (en) * 2012-06-08 2022-02-18 Nitto Denko Corporation Lipids for therapeutic agent delivery formulations
CN107427531A (en) 2015-03-24 2017-12-01 协和发酵麒麟株式会社 Lipid nanoparticle containing nucleic acid
MX2021000644A (en) 2018-07-18 2021-08-19 Manzanita Pharmaceuticals Inc Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2368208A (en) * 1940-12-16 1945-01-30 Emulsol Corp Chemical compounds and method of preparing same
US3265719A (en) * 1959-12-28 1966-08-09 American Cyanamid Co Betaines
DE2651898A1 (en) * 1976-11-13 1978-05-18 Hoechst Ag SOFTENING DETERGENT
US5049386A (en) * 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
DE3618517A1 (en) * 1985-06-04 1986-12-04 Lion Corp., Tokio/Tokyo Emulsifying agent for emulsion polymerisation
US4864060A (en) * 1987-08-31 1989-09-05 Witco Corporation Surface active compounds, methods for making same and uses thereof
US5068431A (en) * 1987-08-31 1991-11-26 Witco Corporation Methods of making new surface active compounds
CA2001401A1 (en) * 1988-10-25 1990-04-25 Claude Piantadosi Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
JPH03181597A (en) * 1989-12-12 1991-08-07 Bridgestone Corp Electric viscous fluid
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
DE4241983C1 (en) * 1992-12-12 1994-03-24 Messer Griesheim Gmbh Shielding gas for the arc welding of aluminum
US5364324A (en) * 1992-12-14 1994-11-15 Boettiger Jr Walter W Exercise device
US5753613A (en) * 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells

Also Published As

Publication number Publication date
CA2251169C (en) 2006-12-19
DK0902780T3 (en) 2002-02-11
ES2166540T3 (en) 2002-04-16
US5994317A (en) 1999-11-30
EP0902780B1 (en) 2001-10-31
DE69707870T2 (en) 2002-07-11
EP0902780A1 (en) 1999-03-24
ATE207874T1 (en) 2001-11-15
WO1997037966A1 (en) 1997-10-16
JP2000508642A (en) 2000-07-11
DE69707870D1 (en) 2001-12-06
JP4031045B2 (en) 2008-01-09

Similar Documents

Publication Publication Date Title
CA2251169A1 (en) Quaternary cytofectins
WO1997019675A3 (en) Complex cationic lipids
CA2180554A1 (en) Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
EP1080231A4 (en) Multimolecular devices, drug delivery systems and single-molecule selection
PL325774A1 (en) Drug delivery system for two or more active substances
AU6385396A (en) Drug mitochondrial targeting agents
HUP0100507A3 (en) Polyethylene glycol-grf conjugates, site-specific preparation thereof, pharmaceutical compositions comprising thereof and their use
AU6140598A (en) Multipathway electronically-controlled drug delivery system
AU2740997A (en) Slow-release, self-absorbing, drug delivery system
IL132991A (en) Substituted pyrazoles, pharmaceutical compositionscomprising them and their use as p38 inase inhibi tors
CA2322579A1 (en) Gelling ophthalmic compositions containing xanthan gum
IL132156A0 (en) Neoglycoproteins
AU9617698A (en) Polymeric systems for drug delivery and uses thereof
AU3290997A (en) Cationic polymer/lipid nucleic acid delivery vehicles
EP0839125A4 (en) Novel cationic lipids and the use thereof
AU1535799A (en) Pharmaceutical hydrogel formulations, drug delivery devices and methods
AU3306695A (en) Weight distributing hitch assembly
AU6120498A (en) 4,4-difluoro-2,3,4,5-tetrahydro-1h-1-benzazepine derivatives and drug compositions containing them
AU6784698A (en) Cationic amphiphiles for intracellular delivery of therapeutic molecules
WO1997037640A3 (en) Uniform drug delivery therapy
AU3825595A (en) Improved iontophoretic drug delivery device
EP0685579A3 (en) Highly crimpable conjugate fibers and nonwoven webs made therefrom.
AU4316696A (en) Polymeric platinum complex, preparation thereof, and anticancer agent comprising thereof
CA2193149A1 (en) Cationic therapuetic agents and delivery systems
AU6874998A (en) Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160408